Skip to main content

Table 1 In vitro cytotoxicity phenotype (ATP depletion) and known in vivo cardiac safety liabilities of the test compounds

From: Assessing the translatability of In vivo cardiotoxicity mechanisms to In vitro models using causal reasoning

Drug ATP depletion IC50 at 48 hrs (μM ± SE) In vivo 5-day treatment (mg/kg) Reported ECG abnormalities & arrhythmia Reported structural cardiotoxicity Primary pharmacology & indication
Amiodarone 12 ± 1.17 147 Yes No Anti-arrhythmic
Amitriptyline 5.7 ± 0.67 160 Yes Yes Tricyclic antidepressant
Cyclosporine 2.71 ± 0.92 350 No Yes Immunosuppressive
Dexamethasone >300 1 No Yes Glucocorticoid
Dobutamine 22.9 ± 0.83 43 Yes Yes β1 agonist, inotropic
Doxorubicin 4.23 ± 0.52 3 Yes Yes Cytotoxic Anti-neoplastic
Loratadine 39.5 ± 2.11 2000 Yes No Anti-histaminic
Mitoxantrone 1.16 ± 0.47 2 Yes Yes Cytotoxic Anti-neoplastic
Terbutaline >300 130 Yes Yes β2 agonist